DoW Multiple Sclerosis Clinical Trial Award
About
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e. g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required. • Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i. e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the propo.
The DoW Multiple Sclerosis Clinical Trial Award supports researchers and clinical teams implementing innovative clinical trials with significant potential to advance multiple sclerosis treatment and management. This Department of Defense-funded program is designed for qualified organizations ready to rapidly translate promising new therapies, drugs, biologics, devices, and emerging technologies into human testing. The award offers two distinct funding levels: Funding Level 1 supports small-scale, proof-of-principle trials including pilot studies and first-in-human research to demonstrate feasibility, while Funding Level 2 supports larger-scale phase 1 and phase 2 trials designed to establish preliminary safety and efficacy evidence. Applicants must address at least one FY26 program focus area and provide preliminary data supporting their proposed clinical trial. This award is ideal for research institutions, clinical centers, and organizations positioned to conduct rigorous clinical investigations that could meaningfully impact MS patient outcomes. If your organization has the infrastructure, expertise, and clinical trial protocol ready for implementation, this competitive funding opportunity can accelerate your multiple sclerosis research from concept to human trials.
Funding Facts
● Applications openDeadline
August 13, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by funding level (FL1 and FL2)
Deadline
2026-08-13
Grant Type
federal
Application Cycle
Annual (FY26 deadline: August 13, 2026)
Best For
Research institutions, medical centers, and clinical organizations conducting multiple sclerosis clinical trials
Frequently Asked Questions
Who is eligible for the DoW Multiple Sclerosis Clinical Trial Award?
Specific eligibility criteria are not provided in available program information. Typically, Department of Defense research awards require eligible institutions such as universities, medical centers, research organizations, and other qualifying entities. For definitive eligibility requirements, including institutional status, investigator qualifications, and any geographic or organizational restrictions, consult the official Department of Defense Multiple Sclerosis Research Program announcement.
How much funding does the DoW Multiple Sclerosis Clinical Trial Award provide?
The award offers two distinct funding levels—Funding Level 1 (CTA-FL1) for small-scale, proof-of-principle trials and Funding Level 2 (CTA-FL2) for larger-scale phase 1 and phase 2 trials—though specific dollar amounts are not detailed in available information. Visit the official DoD MSRP website for current funding ranges and maximum award amounts for each level.
How do I apply for the DoW Multiple Sclerosis Clinical Trial Award?
Applications must address at least one FY26 Multiple Sclerosis Research Program Clinical Trial Award focus area and include preliminary data relevant to your proposed clinical trial. The deadline for FY26 applications is August 13, 2026. Submit your application through the official Department of Defense grants portal or the designated submission system outlined in the current program announcement. Review the complete funding opportunity announcement for detailed submission instructions, required forms, and technical requirements.
What can DoW Multiple Sclerosis Clinical Trial Award funding be used for?
This award funds the implementation of clinical trials evaluating promising new MS treatments and management approaches. Eligible research includes trials of new pharmacologic agents (drugs and biologics), medical devices, clinical guidance innovations, and emerging technologies. Funding Level 1 supports small-scale trials (pilot, first-in-human, phase 0) to demonstrate feasibility, while Funding Level 2 supports phase 1 and 2 trials seeking preliminary evidence of safety or efficacy in relevant patient populations. Contact the DoD MSRP program office for guidance on allowable costs and budget requirements.
Last updated: July 5, 2026